Tweet
Influenza Other Respir Viruses
. 2025 Mar;19(3):e70081.
doi: 10.1111/irv.70081. Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024
Liliana Antunes 1 , Madelyn Rojas-Castro 1 , Marcos Lozano 2 3 , Iván Martínez-Baz 3 4 , Isabel Leroux-Roels 5 6 , Maria-Louise Borg 7 , Beatrix Oroszi 8 , Margaret Fitzgerald 9 , Ralf Dürrwald 10 , Ligita Jancoriene 11 , Ausenda Machado 12 , Goranka Petrović 13 , Mihaela Lazar 14 , Lenka Součková 15 , Sabrina Bacci 16 , Jennifer Howard 1 , Nuno Verdasca 17 , Luca Basile 18 , Jesús Castilla 3 4 , Silke Ternest 5 , Aušra Džiugytė 7 , Gergő Túri 8 , Roisin Duffy 9 , Carolin Hackmann 10 , Monika Kuliese 19 , Verónica Gomez 12 , Zvjezdana Lovrić Makarić 13 , Alexandru Marin 20 , Petr Husa 15 , Nathalie Nicolay 16 , Angela M C Rose 1 ; VEBIS SARI VE network team
Collaborators, Affiliations
We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.
Keywords: case–control study; elderly; severe acute respiratory infections (SARI); test‐negative design; vaccine effectiveness.
. 2025 Mar;19(3):e70081.
doi: 10.1111/irv.70081. Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024
Liliana Antunes 1 , Madelyn Rojas-Castro 1 , Marcos Lozano 2 3 , Iván Martínez-Baz 3 4 , Isabel Leroux-Roels 5 6 , Maria-Louise Borg 7 , Beatrix Oroszi 8 , Margaret Fitzgerald 9 , Ralf Dürrwald 10 , Ligita Jancoriene 11 , Ausenda Machado 12 , Goranka Petrović 13 , Mihaela Lazar 14 , Lenka Součková 15 , Sabrina Bacci 16 , Jennifer Howard 1 , Nuno Verdasca 17 , Luca Basile 18 , Jesús Castilla 3 4 , Silke Ternest 5 , Aušra Džiugytė 7 , Gergő Túri 8 , Roisin Duffy 9 , Carolin Hackmann 10 , Monika Kuliese 19 , Verónica Gomez 12 , Zvjezdana Lovrić Makarić 13 , Alexandru Marin 20 , Petr Husa 15 , Nathalie Nicolay 16 , Angela M C Rose 1 ; VEBIS SARI VE network team
Collaborators, Affiliations
- PMID: 40059069
- DOI: 10.1111/irv.70081
We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.
Keywords: case–control study; elderly; severe acute respiratory infections (SARI); test‐negative design; vaccine effectiveness.